Group 1 - The stock of Shuyu Pingmin has dropped over 18% [1] - Other companies such as Renmin Tongtai, Dajia Weikang, Yingte Group, and Yao Yigou have all seen declines of over 5% [1] - Additional companies including Huaren Health, Zhongyao Holdings, and Kaikai Industrial have also experienced declines [1]

Core Viewpoint - The stock of Chongqing Pharmaceutical Holdings has shown a significant increase in price this year, with a year-to-date rise of 21.68%, despite a recent decline in the last five trading days [1] Group 1: Stock Performance - As of December 26, the stock price reached 6.51 yuan per share, with a market capitalization of 11.25 billion yuan [1] - The stock has experienced a 4.82% decline over the last five trading days, but a 23.53% increase over the last 20 days and a 28.66% increase over the last 60 days [1] - The company has appeared on the trading leaderboard twice this year, with the most recent net purchase of 158 million yuan on December 15 [1] Group 2: Financial Performance - For the period from January to September 2025, the company reported a revenue of 62.21 billion yuan, reflecting a year-on-year growth of 4.22%, and a net profit attributable to shareholders of 384 million yuan, which is a 31.41% increase [2] - The company has distributed a total of 864 million yuan in dividends since its A-share listing, with 294 million yuan distributed in the last three years [3] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 4.05% to 42,000, while the average circulating shares per person increased by 4.22% to 41,112 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 10.09 million shares, an increase of 851,000 shares compared to the previous period [3]

Core Viewpoint - The stock of Chongqing Pharmaceutical Holdings Co., Ltd. has experienced fluctuations, with a recent decline of 2.01% and a year-to-date increase of 18.69% [1] Group 1: Stock Performance - As of December 25, the stock price is reported at 6.35 yuan per share, with a total market capitalization of 10.974 billion yuan [1] - The stock has seen a 7.43% decline over the last five trading days, but a 20.72% increase over the last 20 days and a 24.27% increase over the last 60 days [1] - The company has appeared on the "龙虎榜" (a stock trading leaderboard) twice this year, with the latest instance on December 15, where it recorded a net purchase of 1.58 billion yuan [1] Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 62.211 billion yuan, reflecting a year-on-year growth of 4.22% [2] - The net profit attributable to shareholders for the same period was 384 million yuan, showing a significant year-on-year increase of 31.41% [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders has decreased by 4.05% to 42,000, while the average circulating shares per person increased by 4.22% to 41,112 shares [2] - The company has distributed a total of 864 million yuan in dividends since its A-share listing, with 294 million yuan distributed over the last three years [3] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 10.091 million shares, an increase of 851,000 shares compared to the previous period [3]

证券日报网讯 12月23日，重药控股在互动平台回答投资者提问时表示，目前公司非DTP零售药房业务 正在向综合性健康管理服务平台转型，实现社区健康药房高质量发展。 （文章来源：证券日报） ...

证券代码：000950 证券简称：重药控股 公告编号：2025-091 重药控股股份有限公司 2025年第五次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.本次股东会没有出现否决议案的情形。 2.本次股东会不涉及变更前次股东会决议。 一、会议召开情况 网络投票时间：2025 年 12 月 22 日。其中： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 12 月 22 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 12 月 22 日 9:15-15:00。 （二）会议召开地点：重庆市渝北区金石大道 303 号公司会议室。 （三）会议召开方式：现场投票和网络投票相结合的方式。 （四）会议召集人：公司董事会。 （一）现场会议召开时间：2025 年 12 月 22 日（星期一）14:30。 （五）现场会议主持人：董事刘伟先生。 （六）本次股东会的召开符合《公司法》《深圳证券交易所股票上市规则》 等法律法规、规范性文件及 ...

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 北京市竞天公诚律师事务所 关于重药控股股份有限公司 2025 年第五次临时股东会的 律师见证法律意见书 致：重药控股股份有限公司 北京市竞天公诚律师事务所（以下简称"本所"）接受重药控股股份有限公 司（以下简称"公司"）的委托，指派律师列席公司于 2025 年 12 月 22 日召开的 公司 2025 年第五次临时股东会（以下简称"本次股东会"）。根据《中华人民共 和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《上市公司股东会规则》和《深圳证券交易所股票上市规则》等现行有 关法律、法规、规范性文件以及《重药控股股份有限公司公司章程》（以下简称 "《公司章程》"）的规定，本所律师对公司本次股东会的召集和召开程序、召集 人、出席会议人员的资格、表决程序的合法性、有效性等进行了认真的审查，并 出具本法律意见书。 本所律师根据出席本次股东会所掌握的事实和公司提供的文件资料，按照现 行法律、法规的 ...

Investment Rating - The report maintains a "Neutral" rating for the pharmaceutical and biotechnology industry [1][42]. Core Insights - There is a recovery in demand for clinical research organizations (CROs), while the supply of experimental monkeys is tight, leading to price increases. The domestic financing for innovative drugs is gradually recovering, with a total financing amount of $4.086 billion from January to November 2025, representing a year-on-year increase of 10.6% [1][10]. - The pharmaceutical sector has underperformed compared to the CSI 300 index, with a year-to-date return of 14.49% against the CSI 300's 16.09% [22]. - The current valuation of the pharmaceutical sector is 33.0 times PE based on 2026 profit forecasts, which is a 41% premium over the overall A-share market (excluding financials) [23]. Summary by Sections Recent Trends - The CSI 300 index fell by 0.28% this week, while the pharmaceutical sector decreased by 0.14%, ranking 22nd among 31 primary sub-industries. The weekly performance of sub-sectors includes declines in chemical pharmaceuticals and biological products, while medical services and medical commerce showed gains [9][22]. Market Dynamics - The demand for CROs is recovering, and the supply of experimental monkeys is limited, with prices for 3-5 year old monkeys reaching 140,000 yuan each. This indicates a recovery in the domestic innovative drug research and development environment [10][11]. Valuation - The pharmaceutical sector's current valuation is 29.1 times PE based on trailing twelve months (TTM) earnings, which is below the historical average of 35.0 times PE. The sector has a 17.2% premium over the overall A-share market [23]. Company Performance - Notable performers in the pharmaceutical commercial sector this week include Huaren Health, Luyuan Pharmaceutical, and Shuyuan Pingmin, with significant weekly gains [25]. Key Company Meetings - Upcoming shareholder meetings include Dong'e Ejiao, Zhonghe Holdings, and Yiling Pharmaceutical on December 22, among others [31][32][33].

Market Overview - The A-share market experienced slight fluctuations today, with large-cap blue-chip stocks showing strength, as the Shanghai Composite Index and the Shanghai 50 Index slightly rose, while technology growth stocks faced adjustments, leading to small declines in the ChiNext Index, Sci-Tech 50, and North China 50. The market turnover reached 1.68 trillion yuan [1]. Index Performance - The Shenzhen Component Index closed at 13,053.97, down by 1.29% - The Shanghai Composite Index closed at 3,876.37, up by 0.16% - The ChiNext Index closed at 3,107.06, down by 2.17% - The Sci-Tech 50 Index closed at 1,305.97, down by 1.46% - The North China 50 Index closed at 1,431.71, down by 0.51% [2]. Sector Performance - Active sectors included pharmaceutical commerce, high-dividend stocks, elderly care concepts, and commercial aerospace, while sectors such as Hainan, consumer electronics, glass fiber, and power grid equipment saw the largest declines [2]. - Defense and military industry attracted over 9.5 billion yuan in net inflows, while banking received over 5.5 billion yuan. Other sectors like automotive and biopharmaceuticals also saw significant inflows exceeding 4 billion yuan [3]. Investment Insights - Huazhang Securities noted that historically, years of significant gains see increased volatility in January of the following year, suggesting a potential adjustment phase ahead. Investors are advised to remain patient and await clearer signals for upward trends. The AI industry is highlighted as a stable long-term investment focus [3]. - Guotai Junan emphasized that the spring market typically starts between December and April, with potential early initiation if prior market adjustments and favorable policy expectations align. Current market conditions present a crucial window for positioning in the spring rally [3]. High Dividend Stocks - High-dividend stocks saw a strong performance in the afternoon, with all bank stocks rising. Notable gainers included Shanghai Bank and Chongqing Rural Commercial Bank [4]. - The demand for stable cash flows from long-term funds like insurance and pension funds has increased significantly in a low-interest-rate environment. Insurance companies are projected to increase equity allocations by over 410 billion yuan in the first three quarters of 2025, with high-dividend assets comprising over half of the new positions [4]. Elderly Care Sector - The elderly care concept stocks were notably active, with companies like Jiayou Meikang and Waineng Health hitting their daily limit up of 20% [4]. - The National Health Commission has issued a plan to enhance elderly care services, aiming for a more comprehensive system by 2027 [5]. Silver Economy - The silver economy market in China is projected to reach 8.3 trillion yuan by 2024 and exceed 20 trillion yuan by 2030, with the consumption potential of the elderly population expected to grow to 106 trillion yuan by 2050, positioning China as a leader in the global silver economy market [6]. - CITIC Securities forecasts that the number of new pension recipients will increase by approximately 5.5 to 6 million annually over the next 2-3 years, which will be a significant driver for the silver economy and domestic demand expansion [6].

Market Overview - A total of 61 stocks hit the daily limit up, while 19 stocks faced limit down, resulting in a sealing rate of 76% [1] - The Shanghai Composite Index rose by 0.16%, while the Shenzhen Component Index and the ChiNext Index fell by 1.29% and 2.17% respectively [1] - The total trading volume in the Shanghai and Shenzhen markets was 1.66 trillion, a decrease of 155.7 billion from the previous trading day [1] Stock Performance - Baida Group achieved a six-day limit up streak, while Shengtong Energy and Pinao recorded five and four consecutive limit ups respectively [1][3] - The number of stocks advancing was nearly 2900, with notable performances in the pharmaceutical, banking, and retail sectors [1] - The commercial aerospace concept saw a resurgence, with stocks like Shunhao and Xibu Materials hitting limit up after previous declines [3][5] Sector Analysis - The pharmaceutical commercial sector experienced significant growth due to increased orders amid a rise in respiratory diseases during the winter season [14][15] - The retail sector, particularly driven by the "reward economy," showed strong performance with stocks like Baida Group and Nanjing Shanglv achieving consecutive limit ups [6][12] - The AI healthcare sector remained active, with Ant Group's AI health app "Antifortune" gaining popularity, leading to limit ups for companies like Meian Health and Huaren Health [7][19] Investment Themes - The commercial aerospace sector is highlighted as a strategic emerging industry, with government support and recent rocket launches boosting investor sentiment [5] - The "reward economy" is emerging as a new consumption model among younger demographics, contributing to the growth of related sectors [6][12] - The IP economy is gaining traction, with government initiatives aimed at promoting new consumption models and financial support for innovative businesses [16] Future Outlook - The market is expected to continue experiencing volatility, with a focus on small-cap stocks and growth sectors as larger stocks face profit-taking [9] - The Shanghai Composite Index is attempting to recover above key moving averages, indicating potential for further upward movement if trading volume increases [9]

格隆汇12月18日丨重药控股(000950.SZ)在互动平台表示，公司重药云商主要服务B端终端客户，涵盖单 体药房、中小连锁药房、诊所及基层医疗机构，近年来保持较快的规模增长态势。其通过品类精细化管 理和集约化采购，优化产品结构、稳定毛利水平，辅助提升运营周转效率。 公司DTP处方药房业务整 体发展良好，截至2025年9月末拥有DTP处方药房210家，下属DTP专营子公司实现了盈利。未来公司将 进一步发展DTP药房业务，增强其竞争力，扩大在医药零售领域的市场份额。 ...